ALK (L1196M)

ALK · Variant type: point · HGVS: p.L1196M

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Lorlatinib	100.0%	0.0%	97.24
2	Gilteritinib	99.7%	0.3%	88.97
3	Entrectinib	99.6%	0.4%	93.69
4	Brigatinib	99.5%	0.5%	82.96
5	Repotrectinib	99.4%	0.6%	84.21
6	Ceritinib	99.2%	0.8%	95.44
7	Alectinib	97.3%	2.7%	95.49
8	Crizotinib	96.7%	3.3%	91.39
9	Bosutinib	94.8%	5.2%	87.22
10	Pralsetinib	89.3%	10.7%	93.43
11	Ruxolitinib	86.6%	13.4%	98.25
12	Alpelisib	86.3%	13.7%	97.22
13	Sunitinib	84.8%	15.2%	91.73
14	Neratinib	82.8%	17.2%	93.18
15	Mobocertinib	80.1%	19.9%	97.22
16	Baricitinib	76.9%	23.1%	97.99
17	Nintedanib	74.6%	25.4%	90.23
18	Osimertinib	72.8%	27.2%	97.24
19	Pacritinib	60.6%	39.4%	88.64
20	Tenalisib	54.7%	45.3%	97.98
21	Defactinib	54.1%	45.9%	92.68
22	Vandetanib	48.3%	51.7%	95.74
23	Tepotinib	42.3%	57.7%	99.75
24	Afatinib	34.4%	65.6%	98.50
25	Darovasertib	33.7%	66.3%	96.99

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Lorlatinib	100.0%	97.2%	+2.8%
Gilteritinib	99.7%	99.5%	+0.2%
Entrectinib	99.6%	98.8%	+0.7%
Brigatinib	99.5%	99.2%	+0.2%
Repotrectinib	99.4%	99.4%	+0.0%
Ceritinib	99.2%	98.3%	+1.0%
Alectinib	97.3%	98.6%	-1.3%
Crizotinib	96.7%	97.7%	-1.0%
Bosutinib	94.8%	75.1%	+19.7%
Pralsetinib	89.3%	82.6%	+6.7%
Ruxolitinib	86.6%	52.1%	+34.5%
Alpelisib	86.3%	80.7%	+5.7%
Sunitinib	84.8%	87.7%	-2.9%
Neratinib	82.8%	—	—
Mobocertinib	80.1%	—	—
Baricitinib	76.9%	46.4%	+30.6%
Nintedanib	74.6%	84.9%	-10.3%
Osimertinib	72.8%	80.5%	-7.8%
Pacritinib	60.6%	55.3%	+5.4%
Tenalisib	54.7%	45.2%	+9.5%
Defactinib	54.1%	—	—
Vandetanib	48.3%	—	—
Tepotinib	42.3%	—	—
Afatinib	34.4%	—	—
Darovasertib	33.7%	—	—

Cancer	Organ	Source
carcinoma_lung	Lung	ref
neuroblastoma_autonomic_ganglia	Brain/CNS	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.9ms